-+ 0.00%
-+ 0.00%
-+ 0.00%

Adagio Medical says vCLAS VT ablation trial meets endpoints, posts 84% shock-free rate

PUBT·04/27/2026 10:07:36
Listen to the news
Adagio Medical says vCLAS VT ablation trial meets endpoints, posts 84% shock-free rate
  • Adagio Medical reported positive six-month results from FULCRUM-VT pivotal IDE trial for vCLAS ventricular ablation system.
  • Data were presented at Heart Rhythm Society 2026 conference.
  • Trial met primary safety and effectiveness endpoints, supporting planned FDA Premarket Approval filing for the device.
  • Results showed meaningful reductions in defibrillator shocks plus arrhythmia recurrence, without detailing procedural performance metrics.
  • Readout indicated comparable outcomes across ischemic cardiomyopathy and non-ischemic cardiomyopathy patients, expanding potential addressable market for endocardial-only VT ablation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagio Medical Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-048833), on April 27, 2026, and is solely responsible for the information contained therein.